The extent of likely future global demand for laboratory and office space associated with vaccine research companies has been made clear by new research published today by Savills at part of its Impacts programme, which shows the extent to which venture capital (VC) funding into such companies boomed to US $2.3 billion by the end of August, comprising 1.2% of all global VC investment, up from an annual average of just 0.6% over the past five years.  Article Source

Leave a Reply

Your email address will not be published.